Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide

Strahlentherapie und Onkologie

Volumn 186, Issue 8, 2010, Pages 452-457

  Kopecký, Jindřich ^a   Priester, Peter ^a   Slováček, Ladislav ^a   Petera, Jiří ^a   Kopecký, Otakar ^b   MacIngova, Zuzana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Regional Hospital Nachod   (Czech Republic)

Author keywords

Aplastic anemia; Glioblastoma multiforme; Temozolomide

Indexed keywords

ACICLOVIR; AMIKACIN; CEFOTAXIME; CIPROFLOXACIN; CITALOPRAM; COTRIMOXAZOLE; FLUCONAZOLE; MEROPENEM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; VANCOMYCIN; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; APLASTIC ANEMIA; ARTICLE; BLEEDING TENDENCY; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKOPENIA; LIMB PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PNEUMOCYSTIS PNEUMONIA; RADIATION DOSE; STEREOTACTIC BIOPSY; THROMBOCYTOPENIA; TREATMENT DURATION; BLEEDING DISORDER; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; FRONTAL LOBE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PARIETAL LOBE; RADIATION DOSE FRACTIONATION; SKULL IRRADIATION;

ANEMIA, APLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD CELL COUNT; BRAIN NEOPLASMS; CAUSE OF DEATH; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; DOSE FRACTIONATION; FEMALE; FRONTAL LOBE; GLIOBLASTOMA; HEMORRHAGIC DISORDERS; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PARIETAL LOBE;

EID: 77956622161     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2132-3     Document Type: Article

References (16)

1. T.J. Doyle T. Mikkelsen D. Croteau 2005 Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): report of a phase II trial. ASCO Annual Meeting Proceedings J Clin Oncol 23 1546 10.1200/JCO.2005.02.5841 (Pubitemid 46211501)
2. M.G. Fabrini F. Perrone L. De Franco 2009 Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas Strahlenther Onkol 185 524 9 10.1007/s00066-009-1965-0 19652936
3. E. Fokas U. Wacker M.W. Gross 2009 Hypofractionated stereotactic reirradiation of recurrent glioblastomas. A beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185 235 40 10.1007/s00066-009-1753-x 19370426
4. B.J. George J.B. Eichinger T.J. Richard 2009 A rare case of aplastic anemia caused by temozolomide South Med J 102 974 6 19668033
5. D.E. Gerber S.A. Grossman M. Zeltzman 2007 The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas Neuro Oncol 9 47 52 1:CAS:528:DC%2BD2sXht1Ojs7g%3D 10.1215/15228517- 2006-024 17108062 (Pubitemid 46543488)
6. M.E. Hegi A.C. Diserens T. Gorlia 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 1:CAS:528: DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
7. J.J. Heimans M.J. Taphoorn 2002 Impact of brain tumour treatment on quality of life J Neurol 249 955 60 10.1007/s00415-002-0839-5 12195437 (Pubitemid 35002212)
8. G. Iliadis P. Selviaridis A. Kalogera-Fountzila 2009 The importance of tumor volume in the prognosis of patients with glioblastoma. Comparison of computerized volumetry and geometric models Strahlenther Onkol 185 743 50 10.1007/s00066-009-2015-7 19899008
9. M. Kocher P. Frommolt S.K. Borberg 2008 Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma Strahlenther Onkol 184 572 9 10.1007/s00066-008-1897-0 19016015
10. M. Kocher S. Kunze H.T. Eich 2005 Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma Strahlenther Onkol 181 157 63 10.1007/s00066-005-1314-x 15756519
11. N. Singhal S. Selva-Nayagam M.P. Brown 2007 Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment - case study and review of literature J Neurooncol 85 229 30 1:CAS:528: DC%2BD2sXhtl2gs7rK 10.1007/s11060-007-9403-6 17530175 (Pubitemid 47629406)
12. R. Stupp W.P. Mason M.J. van den Bent 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 96 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
13. M.J. Taphoorn M. Klein 2004 Cognitive deficits in adult patients with brain tumours Lancet Neurol 3 159 68 10.1016/S1474-4422(04)00680-5 14980531 (Pubitemid 38229950)
14. J.A. van Genugten P. Leffers B.G. Baumert 2010 Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice J Neurooncol 96 249 57 1:CAS:528:DC%2BC3cXptl2qtA%3D%3D 10.1007/s11060-009-9956-7 19582373
15. J.L. Villano C.A. Collins E.E. Manasanch 2006 Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide Lancet Oncol 7 436 8 10.1016/S1470-2045(06)70696-9 16648049
16. J.L. Villano T.E. Seery L.R. Bressler 2009 Temozolomide in malignant gliomas: current use and future targets Cancer Chemother Pharmacol 64 647 55 1:CAS:528:DC%2BD1MXptFCksLw%3D 10.1007/s00280-009-1050-5 19543728